Cytokinetics falls 12.7% after third-quarter results showing mixed revenue and a net loss

What happened

Cytokinetics (CYTK) fell 12.7% on November 5, 2026, after third-quarter results showed a narrower net loss and stronger MYQORZO revenue as the company prepared regulatory filings. The company reported a net loss of $1.37 per share versus a Zacks consensus loss estimate of $1.50, and it generated $44.5 million in net revenue from MYQORZO, according to Seeking Alpha and Zacks Investment Research. MYQORZO revenue rose 76% from the prior quarter as the company moved toward potential regulatory submissions to broaden the drug’s use.

How big was the move

The stock closed at $55.55 after falling 12.7% in a session when the S&P 500 fell 4.4% and the healthcare sector median fell 5.7%. Trading volume ran 4.4 times its 20-day average, and the move measured 4.8 times a typical daily move for this stock. Over the last five sessions the stock fell 12.3%, which left it 7.0 percentage points worse than the sector median on the day. Cytokinetics has a market value of $8.76 billion and a beta of 0.86, indicating the stock tends to move less than the market.

The technical picture

The stock traded well below its moving averages: it was 10.6% below its 20-day moving average, 16.0% below its 50-day moving average and 20.7% below its 200-day moving average. The 50-day average is below the 200-day average, a sign of a weak longer-term trend, and the Relative Strength Index (14 days) stood at 30, a level often called oversold. The shares traded 37.1% below the 52-week high and had fallen 9.1% over one month and 27.6% over three months. Volatility ran at 42% annualized over 60 days, which is lower than 77% of its own readings over five years.

Fundamentals and valuation

For the four quarters through September 30, 2026, Cytokinetics reported revenue of $116.6 million, a growth of 33.7% from a year earlier, driven in part by MYQORZO sales. Diluted earnings per share for that period were $-6.04 and the company reported a gross margin of 91.3%, down from 100.0% a year earlier. The company’s operating margin was 604.7% versus 656.9% a year earlier, while free-cash-flow margin was 504.9% and return on invested capital was 39.3%. The company’s share count increased by 15.9% over one year. On valuation the free-cash-flow yield is 6.7%.

Those margin figures and high free-cash-flow metrics reflect accounting and cash characteristics specific to Cytokinetics’ business mix and the timing of product sales and costs. PromtFinance scores rank the company as stronger on Growth at 78 and Revisions at 77, neutral on Quality at 52, and weaker on Value at 33 and Momentum at 31, with Stability at 70. Together, the indicators point to rapid recent revenue growth, a stretched valuation and mixed momentum.

Earnings and analyst expectations

Cytokinetics reported on November 4, 2026, earnings per share of $-1.37 against $-1.43 expected, 4.2% above estimates. That marked two consecutive quarters beating estimates and an average surprise of 2.7% above estimates over the last four reports. Historically the typical two-day reaction after recent reports was that the stock rose 2.3%, but this session’s sharp fall reflected the specifics of the release and broader market weakness. The company’s next scheduled earnings report is February 23, 2027.

Analysts remain broadly constructive despite the session’s sell-off. The consensus price target is $113.33 from 35 analysts, which is 104.0% above the closing price, and the consensus rating is Buy. Ninety-seven percent of analysts rate the stock Buy or Strong Buy. That gap between the consensus target and the current price highlights a divergence between street expectations for future upside and the market’s near-term reassessment of risk.

What to watch

• November 4, 2026: third-quarter report showing EPS of $-1.37 and MYQORZO revenue of $44.5 million (76% quarter-over-quarter increase)
• February 23, 2027: next scheduled earnings report
• Consensus price target of $113.33, which is 104.0% above the closing price and is based on 35 analysts with a consensus rating of Buy
• Percentage of analysts rating the stock Buy or Strong Buy: 97%